Teva's Injection-Free Growth Hormone Shot Wins FDA Approval
Children requiring medication to increase their levels of human growth hormone (hGH) will no longer face the fright and pain of shots, thanks to FDA approval for a Teva Pharmaceuticals' hGH needle-free injection.
Needle-free injectors boost a fine stream of medicated liquid through the skin to the subcutaneous fatty tissue. Then the body absorbs it.
The innovative new injector comes from Antares Pharma, a Swiss-based pharmaceutical company partnering for the first time with Teva.
Teva's lucrative hGH medication Tev-Tropin has been available since 2005, but only through conventional injections. Antares's needle-free injection system, already available in Europe and Asia for insulin administration, makes Teva's new hGH the most child-friendly delivery system on the market.
The United States has the world's largest market for human growth hormone, standing at $1 billion. Tev-Tropin sales in the United States and around the world are in the hundreds of millions of dollars.
Teva shares rose 0.7 percent by mid-afternoon on Wall Street following the announcement.